Interferon beta-1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis:: results of a Markov disease model for Sweden and the UK

被引：0
|
作者：
Kobelt, G
Jönsson, L
Fredrikson, S
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Stockholm Hlth Econ Consulting, Stockholm, Sweden
[3] Huddinge Univ Hosp, Stockholm, Sweden
来源：
JOURNAL OF NEUROLOGY | 2004年 / 251卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [41] Neurotrophic factors in relapsing-remitting and secondary progressive multiple sclerosis patients during interferon-β therapy
    Caggiula, M
    Batocchi, AR
    Frisullo, G
    Angelucci, E
    Patanella, AK
    Sancricca, C
    Nociti, V
    Tonali, R
    Mirabello, M
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S236 - S236
  • [42] Final results from the BETAPAEDIC study of interferon beta-1b for treatment-naive pediatric patients with relapsing-remitting MS
    Gaertner, Jutta
    Brueck, Wolfgang
    Weddige, Andreas
    Hummel, Hannah
    Norenberg, Christiane
    Bugge, Joerg-Peter
    NEUROLOGY, 2017, 88
  • [43] NEDA as a predictor of conversion to secondary progressive multiple sclerosis in patients with relapsing-remitting multiple sclerosis
    Kappos, L.
    Stefano, N. D.
    Sormani, M. P.
    Giovannoni, G.
    Haring, D.
    Tomic, D.
    Meier, D. Piani
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 638 - 639
  • [44] Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis
    Etemadifar, Masoud
    Janghorbani, Mohsen
    Shaygannejad, Vahid
    JOURNAL OF NEUROLOGY, 2007, 254 (12) : 1723 - 1728
  • [45] Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis
    Deisenhammer, F
    Giovannoni, G
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (06)
  • [46] Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis
    M. Etemadifar
    M. Janghorbani
    V. Shaygannejad
    Journal of Neurology, 2007, 254
  • [47] Fatigue predicts conversion to secondary progressive disease phenotype in relapsing-remitting multiple sclerosis patients
    Cavallari, M.
    Palotai, M.
    Prieto, J. C.
    Healy, B. C.
    Egorova, S.
    Polgar-Turcsanyi, M.
    Anderson, M.
    Glanz, B.
    Chitnis, T.
    Guttmann, C. R. G.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 465 - 466
  • [48] Fatigue in Treated and Untreated Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
    Yaldizli, Oe
    Katsarava, Z.
    Vago, S.
    Limmroth, V.
    Putzki, N.
    AKTUELLE NEUROLOGIE, 2008, 35 (09) : 425 - 429
  • [49] UK interferon beta-1b trial for treatment of multiple sclerosis shelved
    Bonn, D
    LANCET, 1996, 348 (9026): : 538 - 538
  • [50] Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
    Zhang, Jian
    Shi, Shengliang
    Zhang, Yueling
    Luo, Jiefeng
    Xiao, Yousheng
    Meng, Lian
    Yang, Xiaobo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
12345